Sardar Imam, MD
Hematology & Oncology · Farmington, NMNPI 1962799775
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,028 of the $24,471 with a category attached, or 65.5%. It is spread thinly across 34 manufacturers, the largest accounting for just 15.7%. Reporting peaked in 2021 at $7,510 and has fallen 99.4% since, to $43 in 2025. Among hematology & oncology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $226.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Janssen Scientific Affairs, LLC$3K
- Pfizer$3K
- Novartis$3K
- Exelixis Inc.$2K
- Karyopharm Therapeutics Inc.$2K
- plus $8K from 28 others
Across 112 payments — averaging $5559.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$367K
- Regeneron$82K
- Genentech, Inc.$68K
- GSK$26K
- Seagen Inc.$19K
- Tesaro, Inc.$18K
- plus $41K from 8 others
What the payments were for
- Consulting fees$16,02865%
- Speaking & faculty fees$5,11021%
- Travel & lodging$1,8277%
- Food & beverage$1,4046%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $3,852 |
| Janssen Scientific Affairs, LLC | 3 | $2,940 |
| Pfizer | 14 | $2,745 |
| Novartis | 6 | $2,555 |
| Exelixis Inc. | 5 | $2,309 |
| Karyopharm Therapeutics Inc. | 1 | $2,250 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,100 |
| AstraZeneca | 5 | $1,820 |
| Seagen Inc. | 3 | $1,411 |
| Johnson & Johnson | 8 | $1,092 |
| Daiichi Sankyo Inc. | 1 | $550 |
| Genentech USA, Inc. | 8 | $123 |
| Merck | 7 | $112 |
| E.r. Squibb & Sons, L.L.C. | 7 | $108 |
| Bristol Myers Squibb | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Gilead | 3 | $40 |
| Sanofi | 2 | $37 |
| Roche Diagnostics Corporation | 1 | $36 |
| Lilly USA, LLC | 2 | $31 |
| Eisai Inc. | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Bayer | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Spectrum Pharmaceuticals Inc. | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Novocure Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $13 |
| EMD Serono, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,471 in reported general payments places this provider in the 90th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 26 | $574,418 |
| RevlimidLenalidomide | 20 | $464,203 |
| TasignaNilotinib Hcl | 18 | $381,518 |
| Lenalidomide | 12 | $184,346 |
| EliquisApixaban | 76 | $53,956 |
| XareltoRivaroxaban | 46 | $35,812 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $4,931 |
| Fentanyl | 16 | $3,279 |
| Letrozole | 103 | $1,669 |
| Hydroxyurea | 27 | $903 |
| Ondansetron Hcl | 31 | $898 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $674 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 18 | $564 |
| Gabapentin | 44 | $467 |
| Acyclovir | 32 | $436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $108 | $574,41826 claims |
| Bristol Myers SquibbRevlimid | $71 | $464,20320 claims |
| NovartisTasigna | $2,555 | $381,51818 claims |
| PfizerEliquis | $2,745 | $53,95676 claims |
| Johnson & JohnsonXarelto | $1,092 | $35,81246 claims |
| AstraZenecaSymbicort | $1,820 | $4,93123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Farmington
- Ankit AnandFarmington$16K
- Jeffrey NeidhartFarmington$6K
- James NeidhartFarmington$11
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Ethan BinderRio Rancho$16K
- Scott HerbertAlbuquerque$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.